|
|
|
NEW TECHNOLOGIES FOR FFPE SAMPLES: Improved RNA Isolation and novel cDNA priming for qPCR and for universal mRNA amplification
1AmpTec GmbH, Hamburg, Germany; 2Department of Clinical Research, University of Bern, Switzerland; 3Xceed Molecular, Toronto, Canada; 4Department of Dentistry, UKSH, Kiel, Germany
Improved FFPE RNA isolation, novel TR priming for complete recovery of FFPE mRNA fragments. Differential expression defines Scores for tumor classification: comparing fresh-frozen with FFPE. Novel flow-through Ziplex microarray platform demonstrates MAQC performance level of data obtained with FFPE samples.
|
FOXP3 Gene Expression in Multiple Sclerosis patients before and after Mesenchymal Stem Cell therapy
Tehran University of Medical Sciences,University of Tehran
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the CNS. No successful treatment for MS, but one therapeutic strategy in research is the use of bone marrow-derived mesenchymal stem cells (MSC). We studied a group of MS patients who underwented MSCs, assayed for expression of a transcription factor, FOXP3, as a specific marker of MS amelioration in peripheral blood. qRT-PCR on PBMCs showed higher FoxP3 levels.
|
miR-21 upregulation and miR-128a downregulation in human glioblastomas
1 Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal 2 Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, Apartado 3126, 30
miRNA deregulation is an important hallmark on cancer development and progression. This work shows that miR-21 is overexpressed is human glioblastoma samples and cell lines, whereas miR-128a is highly downregulated on these tumours. miRNA modulation using antisense oligonucleotides and/or miRNA precursor molecules decreased tumor cell viability. Thus, targeting deregulated miRNAs may constitute a complementary/alternative approach on the treatment of glioblastomas and other miRNA-related maligna
|
|
|
|
|
|
Protein NMR/Biophysics Research Associate (BS/MS)
Novartis Institutes for BioMedical Research
We are committed to discovering innovative medicines to cure disease and improve human health. By hiring the best academic, biotech, and pharmaceutical trained scientists, we have fostered an atmosphere for drug discovery where innovation is rewarded.
|
|
|
Senior Account Manager/Account Director
Alto Marketing
The best career move for a well-connected marketing professional with real leadership ability and drive!
|
|
|
Senior Scientific Marketing Writer - Life Sciences
Alto Marketing
For a challenging career using your advanced life science background and writing strengths, please read on.
|
|
|
Post-doctoral position at INRA (France)
INRA
An 18-month post-doctoral position is available at INRA Clermont-Ferrand-Theix (France).The position is opened to both French and foreign applicants.
|
|
|
Engineer Technician, Fayetteville, Arizona, USA
SFC-Fluidics
SFC Fluidics is looking to hire a highly motivated, detail-oriented engineer technician.
oral communication skills . Experience with GMP and GLP desired
|
|
|
Computational Medicinal Chemistry Post-Doc Position, Siena, Italy
University of Siena
NatSynDrugs Is Seeking Candidates For a Computational Medicinal Chemistry Post-Doc Position
|
|
|
Automation Engineer, Metabolism, Agios Pharmaceuticals, Cambridge, MA, USA
Agios Pharmaceuticals
With new research showing that cancer cells become addicted to using more nutrients than normal cells to promote their rapid growth, there is an unprecedented opportunity to create a new class of oncology therapeutics that target a fundamental and ubiquitous mechanism in cancer cells. The intersection of these two fields of research - cancer and metabolism- represents an important and novel approach to treating cancer.
|
|
|
Senior Scientist, Metabolism
Agios
Agios Pharmaceuticals is seeking a PhD Scientist to join a team that is building and applying a state-of-art approach to investigate the intersection of cancer cell biology and metabolism.
|
|
|
Metabolomics Platform Coordinator, CIBERDEM, Barcelona
CIBERDEM
The Metabolomics Platform is a research facility financed by CIBERDEM, the Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders. CIBERDEM is an initiative of the Carlos III Health Institute (Ministry of Science and Innovation, http://www.isciii.es), while the platform is located at the Universitat Rovira i Virgili (Tarragona, Spain).
|
|
|
Senior Fellow, Long Term Research in Metabolomics and Nutrient
PepsiCo
Establish and lead the LTR Pepsico Biology Innovation Lab (PIBL) Metabolomics and Nutrient Physiology research program and team.
|
|
|
|
RNAi & miRNA Europe
14 September 2010 - 15 September 2010
Now in its 7th year, our popular RNAi Europe conference will be co-located with three others to cover the broad spectrum of RNA research. This year there will be a large focus on the latest research in microRNAs as well as RNAi in cancer and other diseases.
|
Epigenetics Europe
14 September 2010 - 15 September 2010
The second Epigenetics Europe will focus on the most recent discoveries in this field. Speakers will discuss Methylation and DNA silencing, Chromatin remodelling and ncRNA functions as well as highlighting some of the discoveries of epigenetics in disease processes.
|
SBS Biomolecular Screening Symposium
18 October 2010 - 19 October 2010
Advanced Applications Across Academia, Government & Industry
Sheraton Imperial Hotel & Convention Center
Durham, NC, USA
|
RNAi and miRNA World Congress 2011
26 April 2011 - 27 April 2011
Select Biosciences will be hosting its 5th annual RNAi and miRNA World Congress on April 28-29th 2011 in Boston. Topics include:
RNAi therapeutics, target discovery and validation, transfection and in vivo RNAi.
siRNA library screens and microRNAs in disease biology.
Stem cell biology, diagnostics, virology, biogenesis and development.
|
|
| |
|
|
|
|
|
Role of microRNAs in Pancreatic Cancer
Tom Schmittgen, Associate Professor, Ohio State University, speaking at RNAi World Congress 2009
|
|
RNAi in Integrated Genomic Approaches to Cancer
David Root, Director, RNAi Platform and Project Leader, The RNAi Consortium Broad Institute of MIT and Harvard, speaking at RNAi World Congress 2009
|
|
|
Rescue of Pituitary Function in a Mouse Model of Isolate Growth Hormone Deficiency Type II by RNAi
James Patton, Professor, Vanderbilt University, speaking at RNAi World Congress 2009
|
|
|
|
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Pharmavision
This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines.
|
MicroRNA Research and Disease Associations 2010 Market Report
Select Biosciences Ltd
This report contains primary market data characterizing the microRNA research marketplace including market penetrance of different research product vendors into the end-user community, products for microRNA research in the various market segments, research market characteristics—number of experiments performed, research product pricing, segmentation of the microRNA research market across various research areas, and unmet market needs.
|
|
|
|
Nucleofection® Enables Luciferase Reporter Assays in Primary Cells and Virtually Any Cell Line
Amaxa GMBH
The combination of Promega’s luciferase products and amaxa's Nucleofector® Technology enables researchers to obtain much more significant results with physiologically relevant cells. In this technical note, we give suggestions for Nucleofection® of luciferase constructs and an overview about the wide range of possible applications.
|
RNAi-mediated CD2 suppression in primary human T cells
Amaxa GMBH
The down-regulation of gene expression using small interfering RNA (siRNA) has become the method of choice for functional gene analysis in cells. Data presented in this application note show that CD2 expression can be specifically down-regulated in both resting and activated primary human T cells via the Nucleofection® of CD2 specific siRNA molecules.
|
|